Tests THC and CBD oil on thinking and bladder symptoms in multiple sclerosis
Tests THC or CBD oil in adults with multiple sclerosis for thinking and bladder symptoms.
Plain-language title generated from the registry record
Registry title: Cannabis (THC vs. CBD) in Multiple Sclerosis
Key facts
- Where
- Calgary, CanadaSee the 2 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 26 and 59 years old?
Source: NCT06261489, who can take part
Where in Canada
- University Of CalgaryCalgary, CanadaTaking people
- University of Calgary Foothills Medical CenterCalgary, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Calgary
- Trial code
- NCT06261489
- Record updated
- 15 September 2026
- Original description
The goal of this clinical trial is to examine the effect of Cannabis components, THC and CBD, on cognition and bladder symptoms in people with Multiple Sclerosis (MS).Read full original descriptionShow less
The Differential Effects of THC vs. CBD on Cognition in Persons With MS
The goal of this clinical trial is to examine the effect of Cannabis components, THC and CBD, on cognition and bladder symptoms in people with Multiple Sclerosis (MS).
Participants will complete questionnaires and cognitive tests. They will be randomly assigned to receive either CBD or THC oil and will take the study drug for 15 weeks.
Inclusion: Age between 26 and 59 years inclusive; Confirmed diagnosis of Multiple Sclerosis as per McDonald criteria (any type) [12]; Symptoms of neurogenic lower urinary tract dysfunction (NLUTD) as measured by neurogenic bladder symptom score (NBSS), with a minimum score of 7; If already on a medication for NLUTD, must be stable on this medication for at least 4 weeks; Sexually active men and women of child-bearing potential must agree to use adequate contraception; Written informed consent.
Exclusion: Use of antipsychotic medication; Currently using cannabis/CBM less than 3x/week and being unwilling to abstain for the duration of the study; Major psychiatric disorder such as schizophrenia or bipolar disorder; Major neurological disorder which could affect cognition such as dementia, traumatic brain injury; Seizure disorder; Use of benzodiazepines other than exclusively at night/bedtime; Experienced a MS relapse in the last ninety (90) days; Current use of cannabis or CBM greater than 3x/week; Visual acuity (binocular) worse than 20/70 (in order to complete the cognitive outcomes); Significant upper extremity disability that would interfere with the cognitive tests battery; Indwelling catheter use/urinary diversion; Pregnant or Breastfeeding.